证券代码：603392 证券简称：万泰生物 公告编号：2026-001 北京万泰生物药业股份有限公司 第六届董事会第十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 北京万泰生物药业股份有限公司（以下简称"公司"）于2026年1月9日以电 子邮件方式向全体董事发出第六届董事会第十四次会议召开通知和会议材料。本 次会议于2026年1月13日以通讯方式召开。本次会议由公司董事长邱子欣先生主 持，应出席董事9人，实际出席董事9人。本次会议的出席人数、召开和表决方式 符合《公司法》等法律、法规及《公司章程》的相关规定，合法有效。 二、董事会会议审议情况 1、审议通过了《关于使用部分闲置自有资金进行现金管理的议案》 表决结果：同意9票、反对0票、弃权0票。 同意公司在保证正常经营、资金安全的前提下，使用最高额度不超过人民币 45亿元（含）的闲置自有资金适时购买安全性高、流动性好的低风险投资产品。 该额度自公司董事会审议通过之日起12个月内有效，可由公司及全资子公司、控 股子公司共同循环滚动使用。 ...

Core Viewpoint - The company, Zhifei Biological, is facing a severe financial crisis due to a combination of high inventory levels, a rigid procurement agreement with Merck, and increased competition from domestic vaccine manufacturers, leading to a significant decline in sales and market value [1][10][14]. Group 1: Financial Situation - Zhifei Biological is seeking a medium to long-term syndicated loan of up to 10.2 billion yuan, with the controlling shareholder's family providing full guarantees and pledging core subsidiary equity and substantial receivables [1]. - As of the third quarter of 2025, the company had 20.2 billion yuan in inventory and 12.8 billion yuan in receivables, totaling over four times its revenue for that period [2][9]. - The company's revenue dropped from 529.2 billion yuan in 2023 to 260.7 billion yuan in 2024, while it is obligated to fulfill a procurement plan of 32.6 billion yuan for HPV vaccines in 2024 [7][11]. Group 2: Market Dynamics - The partnership with Merck, which began in 2011, initially led to significant revenue growth, with sales increasing nearly 40 times from 2017 to 2023 [3][6]. - The introduction of the domestic nine-valent HPV vaccine by Wantai Biologics in June 2025, priced at 499 yuan per dose, significantly undercut the price of Merck's vaccine, leading to a collapse in sales for Zhifei's products [2][10]. - By 2025, the batch issuance of the four-valent HPV vaccine dropped to zero, and the nine-valent vaccine saw a year-on-year decline of 76.8% in the first half of 2025 [10][11]. Group 3: Future Prospects - The company has invested over 5.1 billion yuan in research and development over the past five years, with a focus on developing its own vaccine products to reduce reliance on Merck [13][14]. - Despite the ongoing development of over thirty self-developed projects, the revenue from these products was only 1.18 billion yuan in 2024, which is negligible compared to the 246.65 billion yuan from agency income [14]. - The company's market capitalization has plummeted from over 400 billion yuan in 2021 to less than 50 billion yuan by early 2026, indicating a drastic decline in investor confidence [14].

Core Viewpoint - The pharmaceutical stock market rebounded significantly in 2025, but Zhifei Biological (300122) experienced a nearly 30% decline, marking the fourth consecutive year of decline for the company, primarily due to a substantial drop in performance leading to losses [1]. Financial Performance - In 2024, Zhifei Biological reported a revenue of 26.1 billion yuan, a year-on-year decrease of 51%, and a net profit of 2.02 billion yuan, down 75% year-on-year [1]. - For the first three quarters of 2025, the company achieved a revenue of 7.63 billion yuan, a year-on-year decline of 66%, and incurred a net loss of 1.2 billion yuan, reversing from profit to loss [1]. - As of the end of Q3 2025, the company's cash on hand was only 2.498 billion yuan, while short-term loans reached 10.318 billion yuan, indicating significant financial pressure [1]. Inventory and Receivables - By the end of Q3 2025, Zhifei Biological's inventory surged to 20.25 billion yuan, compared to only 9 billion yuan at the end of 2023, posing a substantial risk of inventory impairment [2]. - The accounts receivable stood at 12.814 billion yuan, indicating pressure from delayed payments, with over 45% of accounts receivable aging over one year by the end of Q3 2025 [2]. HPV Vaccine Market Dynamics - The company renewed its procurement agreement with Merck to purchase 98 billion yuan worth of HPV vaccines by 2026, but the batch release volume of the four-valent HPV vaccine dropped by 95% year-on-year in 2024, and the nine-valent HPV vaccine saw a 15% decline [1]. - The monopoly of imported nine-valent HPV vaccines was broken in June 2025 when Wantai Biological's domestic nine-valent HPV vaccine was approved, creating direct competition with the Merck vaccine that Zhifei Biological distributes [1]. Financing and Debt Management - To address financial pressures, Zhifei Biological initiated significant financing efforts, including applying for a medium to long-term loan of up to 10.2 billion yuan and issuing bonds to raise no more than 6 billion yuan for operational needs [4][5]. - As of Q3 2025, the total liabilities of the company reached 16.79 billion yuan, with a debt-to-asset ratio of 36.18%. If the new loan is included, the ratio could rise to approximately 48% [5]. - The company utilized all core assets for guarantees related to the loan, including personal guarantees from the controlling shareholders and pledging core subsidiaries' equity and receivables [5]. Research and Development Efforts - In response to challenges, Zhifei Biological is enhancing its innovation capabilities by establishing research and production bases in Beijing, Anhui, and Chongqing, along with an innovation incubation center [5]. - The company's R&D expenses have increased from 300 million yuan in 2020 to 971 million yuan in 2024, with 669 million yuan spent in the first three quarters of 2025 [5].

Macro Strategy - The macro short cycle shows slight signs of turning, but it is still uncertain whether the current cycle has completed its bottoming process. December PPI year-on-year was -1.90%, showing improvement from November's -2.20%, while CPI was 0.80%, remaining in positive territory for the third consecutive month. However, the absolute value is low, keeping the annual CPI growth at 0% [2][3] - The macro short cycle composite index, derived from PMI, PPI, CPI, and 10-year government bond yields, indicates a slight turning point in December, but further observation is needed to confirm the bottoming of the current cycle [2] Stock Market - A-shares achieved a "good start" in the first week of 2026, with major indices showing gains: Shanghai Composite Index up 3.82%, Shenzhen Component Index up 4.40%, and ChiNext Index up 3.89%. The market's positive performance is attributed to early policy support in the "two new" sectors and improving macro indicators [3][4] - The primary industry sectors saw more gains than losses, with aerospace equipment II and wind power equipment leading the way with increases of 24.49% and 20.01%, respectively. The banking sector was the only one to decline, down 1.90% [5] Investment Recommendations - For the long term, 2026 is the starting year of the "14th Five-Year Plan," with a supportive policy environment for industrial upgrades. The market is expected to maintain a "slow bull" trend, with a focus on sectors related to "anti-involution," insurance, securities, and aerospace as guided by the "14th Five-Year Plan" [6] - The new cycle in 2026 is anticipated to benefit upstream cyclical industries, with a positive outlook for sectors such as artificial intelligence and aerospace [6] Vaccine Industry - Recent developments in the vaccine industry include significant progress in multiple pipelines. Notable advancements include the approval of a 24-valent pneumococcal polysaccharide conjugate vaccine by CanSino and the initiation of clinical trials for various vaccines by other companies [9] - The vaccine sector is actively pursuing product iteration and technological advancements, with a focus on filling market gaps and expanding mRNA technology pipelines. This innovation trend supports the long-term construction of product lineups [9] - The vaccine industry is currently facing performance pressures, with a high proportion of Me-too pipelines leading to intense competition and price declines. Companies are adjusting their pipeline strategies to focus on innovative vaccines and multi-valent products [13][14]

Core Viewpoint - The joint release of the "Opinions" by multiple government departments aims to strengthen the construction of data-related disciplines and the digital talent workforce, promoting collaborative development in the data field through application scenarios [1] Group 1: Data Element Industry Development - Guangdong is focusing on the core theme of "deep integration of real and digital data," actively advancing the exploration of the full lifecycle value of data elements [2] - The establishment of the first provincial data element industry association in February 2024 marks a significant step in this direction [2] - The Guangdong Provincial Data Element Talent Training Base, inaugurated in September 2024, serves as a model for collaborative talent training among government, academia, and industry [2] Group 2: Talent Training and Collaboration - By the end of 2024, 290 universities in China will have established big data management and application programs, with 805 universities offering data science and big data majors [3] - The training base is becoming a crucial bridge connecting academia and industry, collaborating with top universities like Peking University and Fudan University [3] - The focus on interdisciplinary approaches in higher education is aimed at enhancing the supply of high-end talent in the digital economy [3] Group 3: Industry-Education Integration - The integration of technology and industry innovation in Shenzhen has created a successful model where training bases and industrial parks are closely linked [4] - The Shenzhen International Data Industry Park collaborates with the training base to incorporate real industry needs into the talent cultivation process [4] - Companies in the park benefit from this collaborative model, enhancing their capabilities through access to talent with both data and industry knowledge [4] Group 4: Future Outlook - The Guangdong Provincial Data Element Talent Training Base aims to leverage its collaborative advantages to build an open and integrated talent ecosystem [5] - This initiative is expected to provide robust talent support for the market-oriented reform of data elements and the development of the digital economy in the Guangdong-Hong Kong-Macao Greater Bay Area and nationwide [5]

Core Viewpoint - The company, Zhifei Biological, is facing significant financial distress due to high inventory levels and a substantial loss, prompting it to seek a loan of up to 10.2 billion yuan to manage its operations and replace existing financing [2][5]. Financial Performance - As of Q3 2025, Zhifei Biological reported a loss of 1.2 billion yuan, with inventory reaching 20.246 billion yuan, a 125% increase from the beginning of 2024 [5]. - Accounts receivable stood at 12.814 billion yuan, leading to a total of 33 billion yuan in combined inventory and receivables, over four times the company's revenue for that period [5]. - The company's revenue for 2024 is projected to decline by over 50% to 26.07 billion yuan, with net profit dropping nearly 75% [5]. Industry Context - The HPV vaccine market has shifted from a supply shortage to an oversupply situation, with sales declining since 2024, impacting Zhifei Biological's ability to sell its inventory [6]. - The introduction of competitive products, such as the domestic HPV vaccine priced at 1,500 yuan, has intensified price competition, further squeezing profit margins [6]. - The industry is undergoing structural adjustments, with only 6 out of 17 vaccine companies being profitable in the first half of 2025 [6][7]. Strategic Response - In response to its financial challenges, Zhifei Biological has prioritized inventory reduction, debt management, and cash recovery as core tasks [9]. - The company is also diversifying its product offerings, with plans to increase the number of self-developed products and expand into the GLP-1 market for diabetes and obesity treatments [9]. - The industry is witnessing a shift from price competition to value competition, with a focus on product quality and differentiation as essential for survival [10][11].

Core Viewpoint - The announcement by Zhifei Biological regarding a loan application of up to 10.2 billion yuan highlights the urgent need to address the company's significant inventory pressure and financial challenges in the context of a struggling vaccine industry [2][5]. Financial Situation - As of Q3 2025, Zhifei Biological reported a loss of 1.2 billion yuan, with inventory levels soaring to 20.246 billion yuan, a 125% increase from the beginning of 2024 [5]. - Accounts receivable reached 12.814 billion yuan, leading to a total of 33 billion yuan in combined inventory and receivables, over four times the company's revenue for that period [5]. - The company's asset-liability ratio is projected to rise from 36.18% to approximately 48% following the loan, nearing historical highs [5]. Industry Context - The HPV vaccine market has shifted from a supply shortage to an oversupply, with sales declining since 2024, exacerbated by price competition from new entrants like Wantai Biological [6]. - The price of the two-valent HPV vaccine has plummeted over 90%, from 329 yuan per dose in 2022 to 27.5 yuan in 2025, significantly impacting profit margins [6]. - The vaccine industry is undergoing structural adjustments, with only 6 out of 17 listed vaccine companies profitable in the first half of 2025 [6][7]. Strategic Response - Zhifei Biological has prioritized inventory reduction, debt repayment, and cash recovery as core tasks, launching vaccination campaigns to stimulate demand [9]. - The company is also focusing on diversifying its product offerings, with plans to increase the number of self-developed products in the next three to five years [9]. - A shift towards developing higher-tier vaccines and creating technological barriers is deemed essential for long-term survival in the competitive landscape [10][11]. Market Dynamics - The industry is experiencing a deep restructuring, with many companies expanding into international markets to seek new growth opportunities [9]. - The reliance on single products and agency models has been identified as a significant risk, emphasizing the need for better inventory management and market forecasting capabilities [11].

Core Viewpoint - The article highlights the financial distress faced by Zhifei Biological Products Co., Ltd., which is seeking a loan of up to 10.2 billion yuan to address its significant inventory and operational challenges, reflecting broader issues within the Chinese vaccine industry [1][5]. Financial Situation - As of Q3 2025, Zhifei Biological reported a staggering inventory balance of 20.246 billion yuan, a 125% increase from the beginning of 2024, alongside accounts receivable of 12.814 billion yuan, totaling 33 billion yuan, which is over four times its revenue for that period [5][6]. - The company has experienced a continuous decline in performance, with revenue dropping over 50% to 26.07 billion yuan in 2024 and a net profit decrease of nearly 75%. By Q3 2025, it recorded a cumulative loss of 1.2 billion yuan [5][6]. Inventory and Market Challenges - The core product, the nine-valent HPV vaccine, has a shelf life of three years, with a significant number of vaccines set to expire in 2026, potentially leading to large-scale bad debt provisions [5][6]. - The HPV vaccine market has shifted from a supply shortage to an oversupply situation, with sales declining since 2024, exacerbated by price wars initiated by competitors [6][8]. Industry Dynamics - The vaccine industry is undergoing structural adjustments, with many companies facing similar challenges. In the first half of 2025, only 6 out of 17 listed vaccine companies were profitable, while 5 reported losses [6][8]. - The price of the two-valent HPV vaccine has plummeted from 329 yuan per dose in 2022 to 27.5 yuan in 2025, a decline of over 90%, indicating intense price competition [6][8]. Strategic Responses - In response to its financial crisis, Zhifei Biological has prioritized inventory reduction, debt recovery, and lowering liabilities, launching vaccination campaigns across various regions [8][9]. - The company is also focusing on diversifying its product offerings and reducing reliance on agency business, with plans to increase the number of self-developed products in the next three to five years [8][9]. Future Outlook - The article suggests that the vaccine industry is in a critical phase of reshaping, where companies with strong R&D capabilities and diversified product lines will emerge as winners. However, managing inventory and cash flow remains a pressing concern for survival in the short term [9].

Core Viewpoint - The announcement by Zhifei Biological (300122) regarding a loan application of up to 10.2 billion yuan highlights the urgent need to address a significant inventory pressure of approximately 20 billion yuan in the context of a 1.2 billion yuan loss in Q3 2025, reflecting the challenges faced by the Chinese vaccine industry amid supply-demand imbalances and price wars [1][4]. Group 1: Financial Situation - As of Q3 2025, Zhifei Biological reported a staggering inventory balance of 20.246 billion yuan, a 125% increase from 8.986 billion yuan at the beginning of 2024, with accounts receivable reaching 12.814 billion yuan, resulting in a total of 33 billion yuan, which is over four times the revenue for that period [4]. - The company's revenue for 2024 is projected to decline by over 50% to 26.07 billion yuan, with net profit plummeting nearly 75%, and by Q3 2025, the cumulative loss has expanded to 1.2 billion yuan [4]. - The proposed 10.2 billion yuan loan will increase the company's debt ratio from 36.18% to approximately 48%, nearing historical peaks, indicating severe financial strain [4]. Group 2: Market Dynamics - The HPV vaccine market, once a profit engine, has shifted from a supply shortage to overcapacity, with sales declining since 2024, leading to a situation where Zhifei Biological is compelled to purchase vaccines it cannot sell due to prior high-volume procurement agreements [5]. - The competitive landscape has intensified with the introduction of domestic HPV vaccines at significantly lower prices, such as the 1,500 yuan full-course price of Wantai Biological's product, alongside drastic price reductions in other vaccine categories due to centralized procurement policies [6]. - The vaccine industry is undergoing a deep restructuring, with only 6 out of 17 listed vaccine companies remaining profitable in the first half of 2025, while many others face revenue declines exceeding 50% [5][6]. Group 3: Strategic Responses - In response to the crisis, Zhifei Biological has prioritized inventory reduction, cash recovery, and debt reduction, launching vaccination initiatives across various regions, although challenges remain due to the industry-wide supply-demand imbalance [7]. - The company is accelerating the launch of its own products, aiming to increase the proportion of self-developed products in its revenue mix over the next three to five years, with significant products already in the application stage [7]. - The industry is witnessing a divergence in strategies, with many companies exploring overseas markets for growth, while experts emphasize the need for innovation and higher-tier vaccine development to survive the ongoing market reshuffle [8].

Core Viewpoint - The company, Zhifei Biological, is seeking a loan of up to 10.2 billion yuan to address significant inventory pressures and operational funding needs amid a challenging market environment for the vaccine industry [2][3]. Financial Situation - As of Q3 2025, the company reported a loss of 1.2 billion yuan, with inventory levels soaring to 20.246 billion yuan, a 125% increase from the beginning of 2024 [3]. - Accounts receivable reached 12.814 billion yuan, leading to a total of 33 billion yuan in combined inventory and receivables, over four times the company's revenue for that period [3]. - The company’s revenue is projected to decline by over 50% to 26.07 billion yuan in 2024, with net profit dropping nearly 75% [3]. - The proposed loan will increase the company's debt ratio from 36.18% to approximately 48%, nearing historical highs [3]. Industry Context - The vaccine industry is undergoing structural adjustments, with the HPV vaccine market shifting from high demand to oversupply, leading to significant sales declines for Zhifei Biological [4]. - The introduction of competitive domestic vaccines has intensified price wars, with the price of the two-valent HPV vaccine dropping over 90% from 329 yuan per dose in 2022 to 27.5 yuan in 2025 [4]. - The industry is experiencing a deep restructuring, with only 6 out of 17 listed vaccine companies profitable in the first half of 2025 [5]. Strategic Responses - The company has prioritized inventory reduction, cash recovery, and debt reduction as core tasks, launching vaccination initiatives across multiple regions [5][6]. - Long-term strategies include reducing reliance on agency business and accelerating the launch of self-developed products, with plans to increase the number of proprietary products in the next three to five years [6]. - The company is also diversifying into the GLP-1 sector for diabetes and obesity treatments, aiming to create a "prevention + treatment" ecosystem [6]. Market Dynamics - The industry is witnessing a divergence in corporate strategies, with many companies expanding into overseas markets to seek new growth opportunities [7]. - A shift from price competition to value competition is anticipated, with calls for a ban on bidding below cost price, although the effectiveness of such policies remains uncertain [7]. - The current situation serves as a warning for the industry, highlighting the risks of over-reliance on single products and agency models, emphasizing the importance of inventory management and market forecasting capabilities [7].